Compositions, reaction mixtures and methods for detecting nucleic acids from multiple types of human papillomavirus
First Claim
Patent Images
1. A method of detecting the presence of human papillomavirus (HPV) nucleic acid present in a biological sample, comprising the steps of:
- (a) contacting HPV nucleic acid in a biological sample with a combination of amplification oligonucleotides that amplify a HPV target sequence in an E6/E7 target region sequence, comprising one of the following combinations of amplification oligonucleotides;
(1) amplification oligonucleotides comprising oligonucleotide sequences consisting of SEQ ID Nos. 21, 23, 25, 29, 31, 33, 35, 37, 38, 39, 40, 41, and 42, sequences that are completely complementary thereto, RNA equivalents thereof, or RNA equivalents of the sequences that are completely complementary thereto;
or(2) amplification oligonucleotides comprising oligonucleotide sequences consisting of SEQ ID Nos. 19, 21, 23, 25, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary thereto, RNA equivalents thereof, and RNA equivalents of the sequences that are completely complementary thereto;
(b) producing amplified product from the HPV nucleic acid by using the amplification oligonucleotides and a nucleic acid polymerase in an in vitro amplification reaction; and
(c) detecting the amplified product to indicate the presence in the sample of an HPV nucleic acid in the biological sample.
2 Assignments
0 Petitions
Accused Products
Abstract
Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.
-
Citations
11 Claims
-
1. A method of detecting the presence of human papillomavirus (HPV) nucleic acid present in a biological sample, comprising the steps of:
-
(a) contacting HPV nucleic acid in a biological sample with a combination of amplification oligonucleotides that amplify a HPV target sequence in an E6/E7 target region sequence, comprising one of the following combinations of amplification oligonucleotides; (1) amplification oligonucleotides comprising oligonucleotide sequences consisting of SEQ ID Nos. 21, 23, 25, 29, 31, 33, 35, 37, 38, 39, 40, 41, and 42, sequences that are completely complementary thereto, RNA equivalents thereof, or RNA equivalents of the sequences that are completely complementary thereto;
or(2) amplification oligonucleotides comprising oligonucleotide sequences consisting of SEQ ID Nos. 19, 21, 23, 25, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary thereto, RNA equivalents thereof, and RNA equivalents of the sequences that are completely complementary thereto; (b) producing amplified product from the HPV nucleic acid by using the amplification oligonucleotides and a nucleic acid polymerase in an in vitro amplification reaction; and (c) detecting the amplified product to indicate the presence in the sample of an HPV nucleic acid in the biological sample. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification